Axovant Gene Therapies Ltd (NASDAQ:AXGT) – Analysts at Jefferies Financial Group raised their Q1 2020 earnings estimates for Axovant Gene Therapies in a report released on Wednesday, June 12th. Jefferies Financial Group analyst M. Yee now anticipates that the company will earn ($0.70) per share for the quarter, up from their prior forecast of ($1.20). Jefferies Financial Group also issued estimates for Axovant Gene Therapies’ Q2 2020 earnings at ($0.84) EPS, Q3 2020 earnings at ($0.98) EPS, Q4 2020 earnings at ($0.96) EPS, FY2020 earnings at ($3.49) EPS and FY2021 earnings at ($3.65) EPS.
AXGT has been the subject of a number of other reports. Guggenheim started coverage on Axovant Gene Therapies in a report on Friday, February 15th. They set a “buy” rating and a $56.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $56.00 price objective on shares of Axovant Gene Therapies in a report on Tuesday, March 12th. ValuEngine upgraded Axovant Gene Therapies from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 9th. JMP Securities increased their price objective on Axovant Gene Therapies from $8.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, June 6th. Finally, Cowen reiterated a “hold” rating on shares of Axovant Gene Therapies in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Axovant Gene Therapies currently has an average rating of “Buy” and an average price target of $36.20.
NASDAQ:AXGT opened at $4.85 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. The stock has a market cap of $95.22 million, a P/E ratio of -0.60 and a beta of 1.39. Axovant Gene Therapies has a 52-week low of $3.81 and a 52-week high of $33.12.
Axovant Gene Therapies (NASDAQ:AXGT) last announced its quarterly earnings results on Tuesday, June 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.70) by $1.25.
Large investors have recently bought and sold shares of the stock. ExodusPoint Capital Management LP bought a new position in shares of Axovant Gene Therapies during the first quarter worth about $41,000. Jane Street Group LLC bought a new position in shares of Axovant Gene Therapies during the first quarter worth about $48,000. Marshall Wace LLP bought a new position in shares of Axovant Gene Therapies during the first quarter worth about $272,000. Morgan Stanley bought a new position in shares of Axovant Gene Therapies during the first quarter worth about $291,000. Finally, Macquarie Group Ltd. bought a new position in shares of Axovant Gene Therapies during the first quarter worth about $1,150,000.
About Axovant Gene Therapies
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.